Drug Profile
Istaroxime - Windtree Therapeutics
Alternative Names: Debio 0614; ISTA; PST-2744; ST-2744Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Developer sigma-tau SpA; Windtree Therapeutics
- Class Amines; Androstanes; Cardiovascular therapies; Cyclopentanes; Heart failure therapies; Imines; Ketosteroids; Oximes; Phenanthrenes; Small molecules
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants; Sodium potassium exchanging ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute heart failure; Cardiogenic shock; Decompensated heart failure